Michael S. Hofman, MBBS, on LuPSMA vs Cabazitaxel: Clinical Implications of the ANZUP 1603 Prostate Cancer Trial

Posted: Sunday, May 31, 2020

Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses LuPSMA as a more active agent than cabazitaxel in men with docetaxel-treated metastatic castration-resistant prostate cancer, differences in these treatment approaches, and whether supportive measures were needed for toxicities in the investigational drug.